Matches 1 - 50 out of 204 1 2 3 4 5 >


Match Document Document Title
US20110293723 SYNTHETIC NANOCARRIER COMBINATION VACCINES  
Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are...
US20150174229 INACTIVATED MYCOBACTERIA FOR ORAL USE IN THE PREVENTION OF TUBERCULOSIS  
An inactivated mycobacteria for oral use in the prevention of tuberculosis, which are administered using a multi-dose regimen and with a reduced time interval between doses, such as to induce a...
US20110189208 TB VACCINE  
The invention relates to a vaccine useful in therapy and prevention of mycobacterial infections.
US20140356397 Immunogenic Treatment Of Cancer  
The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously,...
US20110064723 Formulation for room temperature stabilization of a live attenuated bacterial vaccine  
This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are...
US20110110979 METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES  
The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus...
US20110052637 PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS VACCINES  
The present invention is directed to proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as vaccines.
US20140322268 SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS  
Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5,...
US20130337011 RECOMBINANT MYCOBCTERIUM AS A VACCINE  
The invention relates to a recombinant Mycobacterium cell for use as a vaccine.
US20110117119 NOVEL COMPOSITIONS AND METHODS  
The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c...
US20140178423 NOVEL COMPOSITIONS AND METHODS  
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c...
US20110223200 NOVEL COMPOSITIONS AND METHODS  
The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c...
US20120321656 OLIGOPEPTIDES AND THEIR USE FOR TREATING INFECTIOUS DISEASES  
The invention discloses identification, method of making and therapeutic use of synthetic oligopeptides for the treatment of infectious diseases, in particular tuberculosis. The oligopeptides are...
US20110311478 Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium  
The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become...
US20130058997 VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT  
Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant...
US20120003268 SYNERGISTIC COMBINATION AND METHOD THEREOF  
A method for the treatment of myeloma and thymoma by administering a therapeutically effective dose of Mycobacterium indicus pranii with Cyclophosphamide. This disclosure generally relates to the...
US20110250224 ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES  
The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis...
US20110117133 Novel Recombinant BCG Tuberculosis Vaccine Designed to Elicit Immune Responses to Mycobacterium Tuberculosis in all Physiological Stages of Infection and Disease  
A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or...
US20110206712 TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF  
The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c...
US20130052229 COMPOUNDS AND METHODS FOR DIAGNOSIS AND IMMUNOTHERAPY OF TUBERCULOSIS  
Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one...
US20140356395 METHODS AND MATERIALS FOR PRODUCING IMMUNE RESPONSES AGAINST POLYPEPTIDES INVOLVED IN ANTIBIOTIC RESISTANCE  
This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in...
US20150224188 USE OF MEMBRANE VESICLE-BASED VACCINE AGAINST M. TUBERCULOSIS  
Provided are compositions comprising a plurality of isolated mycobacterium membrane vesicles, and methods of use thereof, and methods of improving the efficacy of immunizations. Throughout this...
US20110027349 POLYPEPTIDE VACCINE AND VACCINATION STRATEGY AGAINST MYCOBACTERIUM  
A vaccine is provided wherein a polypeptide or combination of peptides from M. tuberculosis is administered to a subject to elicit an immune response. The polypeptide vaccine is administered as...
US20130330375 Therapeutic Cancer Vaccine  
The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer...
US20130045228 VACCINE FOR PROTECTION AGAINST LAWSONIA INTRACELLULARIS  
The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer...
US20150246080 TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH ISOLATED MYCOBACTERIUM  
The present invention relates to treatment or prevention of post-traumatic stress disorder (PTSD). In particular, the present invention relates to an isolated Mycobacterium, for use in the...
US20110081382 TREATMENT AND PREVENTION OF TUBERCULOSIS  
The invention is within the field of immunology and microbiology, more specifically the field of mycobacteriology and is related to immunotherapy and prophylaxis of tuberculosis and related...
US20140227324 USE OF AN IL12 RECEPTOR-BETA 1 SPLICE VARIANT TO DIAGNOSE ACTIVE TUBERCULOSIS  
The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a method of identifying an active M....
US20120189662 Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti  
The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle...
US20120141533 MYCOBACTERIAL MUTANTS INDUCING IL-12  
Provided are mycobacteria deleted in at least a portion of a region 3 ESAT-6-like gene cluster. Also provided are mycobacteria comprising a mutation in an roc-1 gene. Additionally, vaccines...
US20100310585 THE USE OF MONOMYCOLYL GLYCEROL (MMG) AS AN ADJUVANT  
Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at...
US20130101623 ATTENUATED MYCOBACTERIAL STRAIN AS NOVEL VACCINE AGAINST TUBERCULOSIS  
The present invention provides a novel attenuated vaccine for tuberculosis. Furthermore, when used as a subcutaneous vaccine, the present invention induces a higher level of protection than the...
US20150258187 Tuberculosis Vaccine And Method Of Using Same  
Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is than formulated for...
US20130273110 Tuberculosis Vaccine And Method Of Using Same  
Provided is a pharmaceutical composition that includes one or more inactivated Mycobacterium spp., which are preferably inactivated using gamma irradiation, and which is than formulated for...
US20130142825 METHOD OF PREVENTING AND TREATING INFLAMMATORY DISEASES AND DISORDERS WITH ABSCISIC ACID  
The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide...
US20110135578 MYCOBACTERIAL INFECTIONS  
The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's...
US20110262361 EFFECTIVE NEW DRUG TARGET FOR THE TREATMENT OF TUBERCULOSIS  
The present invention allows a screening method for identifying novel drugs for the treatment of tuberculosis as well as a diagnostic method for identifying clinical strains that are resistant to...
US20110104180 NEW VACCINE FOR THE TREATMENT OF MYCOBACTERIUM RELATED DISORDERS  
The invention relates to genes and proteins involved in the sporulation of Mycobacteria and the use thereof in the technical fields of immunology and medicine. A vaccine comprising spore forming...
US20150202276 METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS  
Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional...
US20120244182 USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION  
The invention provides immunostimulatory compositions and methods of administration thereof. Also provided are methods of administering a tryptanthrin compound in an effective amount to enhance...
US20110311477 Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies  
The present invention provides novel immunotherapeutic compositions and methods useful for treating or preventing microbial infections, weakened immune systems, diseases in which cells have become...
US20150071873 Cancer Treatment by Immunotherapy With BCG or Antigenically Related Non-Pathogenic Mycobacteria  
A first and a second identical or different mycobacterial immunogenic compositions, each comprising at least a Mycobacterium bovis bacillus Calmette-Guerin (BCG), an antigenically related...
US20140147468 LPRG AS A CHAPERONE OF IMMUNE ADJUVANTS  
An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to...
US20130149376 VACCINE COMPOSITION BASED ON STICHOLYSIN ENCAPSULATED INTO LIPOSOMES  
The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into...
US20150140039 IMMUNOLOGICAL MARKERS FOR ADJUVANT THERAPY IN MELANOMA  
The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more SNPs in particular...
US20120128720 MYCOBACTERIUM MUTANTS FOR VACCINES WITH IMPROVED PROTECTIVE EFFICACY  
Tuberculosis (TB) is a major health problem and currently, the only licensed TB vaccine is Mycobacterium bovis Bacille Calmette-Guerin (M. bovis BCG). In the present invention, mutation of...
US20120045476 LIVE ATTENUATED MYCOPLASMA STRAINS  
The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase,...
US20130022638 Tuberculosis Vaccine  
The present invention relates to an isolated microorganism belonging to the genus Mycobacterium, characterized in that it comprises inactivating the gene Rv0757 that confers a PhoP− phenotype and...
US20120039925 TUBERCULOSIS TB VACCINE TO PREVENT REACTIVATION  
The present invention discloses a vaccine or immunogenic composition that can be administered to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by...
US20110243992 METHODS OF ENHANCING THE IMMUNOGENICITY OF MYCOBACTERIA AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUBERCULOSIS, AND FIBROSING LUNG DISEASES  
Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic...

Matches 1 - 50 out of 204 1 2 3 4 5 >